Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 14, 2020

Maastricht University launches AI tool for Covid-19 patient triage

The Department of Precision Medicine at Maastricht University in the Netherlands has launched an artificial intelligence (AI) tool for Covid-19 patient triage.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.


The Department of Precision Medicine at Maastricht University in the Netherlands has launched an artificial intelligence (AI) tool for Covid-19 patient triage.

Developed by the D-Lab group of the Department of Precision Medicine, the personalised medicine platform enables risk assessment of Covid-19 patients. It can integrate various types of available medical data and assess the risk of severe disease that needs mechanical ventilation.

Maastricht University Department of Precision Medicine head professor Philippe Lambin said: “We are excited to be participating in the global fight against the Covid-19 pandemic with our Decision Support System for risk assessment of Covid-19 patients.

“We have repurposed our AI methods, usually applied to oncology questions, to the Covid-19 pandemic.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Meanwhile, the department recently received €920,000 (£814,965) from the European Commission for the DRAGON project.

The project uses AI and machine learning to provide a decision support system for better and more rapid Covid-19 diagnosis and prognosis.

The patient empowerment-centred decision support system will enable multiple stakeholders to participate in improved and more rapid diagnosis. In addition, it is said to improve the scope of precision medicine for accelerated development of new therapies.

The university added that the citizens and patients will be involved in system development.

Department of Precision Medicine Virtual Trial Unit head Dr Cary Oberije said: “One of our missions will be to coordinate an international prospective biomarker trial on Covid-19 patients. We want to understand this virus better and use this knowledge for future outbreaks, also for other viruses.”

The project will be supported by deploying a federated machine learning system, a technology developed in Maastricht by Lambin’s group. It will enable the GDPR-compliant use of multinational data resources.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU